Cancer BiologybioRxivPreprint
Therapeutic vulnerability to PARP1/2 inhibition in RB1-mutant osteosarcoma
G. Zoumpoulidou, C. A. Mendoza, C. Mancusi…·S. Mittnacht
This study shows RB1-mutant osteosarcoma is hypersensitive to PARP1/2 inhibitors, with sensitivity linked to replication checkpoint activation rather than homologous repair defects.
DOI 10.1101/2020.12.28.424497